A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis

“Preliminary results – released at the 48th Union Conference on Lung Health – from Stage 1 of the STREAM randomized clinical trial show that the nine-month treatment regimen being tested achieved favorable outcomes in almost 80 percent of those treated.The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen recommended in the 2011 WHO guidelines, when both regimens are given under trial conditions.

The STREAM trial – initiated by The Union in 2012 with its main partner, the Medical Research Council Clinical Trials Unit at UCL, is the world’s first multi-country randomised clinical trial to test the efficacy, safety and economic impact of shortened multidrug-resistant tuberculosis (MDR-TB) treatment regimens.”

Read the full announcement here.

Recent News and Announcements

Join RESIST-TB at the IUATLD DR-TB Working Group Second Annual Meeting

Click here for a full schedule of MDR-TB related events at the Union Meeting  

IN THE NEWS: NIH funds SLU research of possible treatment for drug-resistant TB

“Saint Louis University is leading a multi-national clinical trial of what could become a regimen for drug resistant tuberculosis that does not require injectable medications. The project is funded by a $6.4 million task order from the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health. Saint Louis University, […]

J&J partners with CSIR-IMTECH on TB treatments

“The Indian subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ) announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new tuberculosis (TB) treatments. Under the Memorandum of […]

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study

“This study forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12·4% in India, 8·9% in the Philippines, 32·5% in Russia, and 5·7% in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% in India, 9·0% in the Philippines, […]

TB makes the G20 Declaration

On 7 & 8th July 2017, leaders of the G20 met in Hamburg, Germany, to address major global economic challenges and to contribute to prosperity and well-being. Their Declaration, published on July 8, carries an important section on combatting antimicrobial resistance (AMR): “AMR represents a growing threat to public health and economic growth. To tackle the spread […]

Event Calendar

Social Media